ArticleEthiopian journal of health sciences2023
Ceftaroline Susceptibility among Isolates of MRSA: A Comparison of EUCAST and CLSI Breakpoints.
Article in Ethiopian journal of health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 citations in OpenAlex.
- Antimicrobial Resistance in Major Gram-Positive Pathogens: Beyond the Vancomycin Border.Antibiotics (Basel, Switzerland) · 2026Review
- Article
- Ceftaroline Exhibits PromisingInternational journal of microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methicillin-resistant Staphylococcus aureus (MRSA) is an important bacterial pathogen causing a number of community-acquired and nosocomial infections. Ceftaroline fosamil is a fifth generation cephalosporin, approved for the treatment of infections caused by MRSA. The main objective of this study was to estimate the susceptibility of ceftaroline among isolates of MRSA by using CLSI and EUCAST breakpoints. Materials and Methods: Fifty non-duplicate isolates of MRSA were included in the study. Ceftaroline susceptibility was done using E-strip test and interpreted using CLSI and EUCAST breakpoints. Results: Susceptible isolates were equal (42%) by both CLSI and EUCAST, while resistant isolates were more commonly seen in EUCAST (50%). Ceftaroline MIC ranged from 0.25- >32µg/ml. All the isolates were sensitive to Teicoplanin and Linezolid. Conclusions: Resistant isolates were less (30%) while using the CLSI 2021 criteria probably due to the inclusion of SDD category. Our study showed that Fourteen isolates (28%) had Ceftaroline MIC >32µg/ml, which is an alarming finding. The high percentage of Ceftaroline resistant isolates in our study probably suggest a hospital spread of Ceftaroline resistant MRSA emphasizing the need for stringent infection control precautions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.